DalsnaFinance Account

Danaher Corporation $DHR

Health Care · Life Sciences Tools & Services · NYSE/NASDAQ

S&P 500 Russell 1000 Washington, D.C.

Create a scorecard

$231.50

+6.81 (+3.03%)

As of Oct 15, 2026, 10:25 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 9, 2026, the first target we tracked for DHR.

Danaher Corporation (DHR) is trading up at $231.50 (+3.03%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on DHR

One firm's current price target on Danaher Corporation: $250 — 8% above the current $232. Each is tracked to its date and scored the same way a member's call is.

UBS $205 → $250 by Sep 2027 Buy Sep 9, 2026 via Investing.com · UBS's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Danaher Corporation revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Danaher Corporation annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$16.9B	$18.3B	$19.9B	$17.9B	$22.3B	$24.8B	$26.6B	$23.9B	$23.9B	$24.6B
Growth (year over year)	+17.0%	+8.6%	+8.5%	−10.0%	+24.4%	+11.3%	+7.4%	−10.3%	−0.1%	+2.9%
Gross profit	$9.33B	$8.57B	$9.51B	$9.98B	$12.5B	$15.2B	$16.2B	$14.0B	$14.2B	$14.5B
Gross margin	55.3%	46.8%	47.8%	55.7%	56.0%	61.4%	60.8%	58.7%	59.5%	59.1%
Operating income	$2.74B	$2.57B	$3.06B	$3.27B	$4.23B	$6.38B	$7.54B	$5.20B	$4.86B	$4.69B
Operating margin	16.2%	14.0%	15.4%	18.3%	19.0%	25.7%	28.3%	21.8%	20.4%	19.1%
Net income	$2.55B	$2.49B	$2.65B	$3.01B	$3.65B	$6.43B	$7.21B	$4.76B	$3.90B	$3.61B
Net margin	15.1%	13.6%	13.3%	16.8%	16.4%	25.9%	27.1%	19.9%	16.3%	14.7%
EPS (diluted)	$3.65	$3.53	$3.74	$4.05	$4.89	$8.61	$9.66	$6.38	$5.29	$5.05
Balance sheet
Cash and equivalents	$963.7M	$630.3M	$787.8M	$19.9B	$6.04B	$2.59B	$6.00B	$5.86B	$2.08B	$4.62B
Total assets	$45.3B	$46.6B	$47.8B	$62.1B	$76.2B	$83.2B	$84.3B	$84.5B	$77.5B	$83.5B
Total liabilities	$22.2B	$20.3B	$19.6B	$31.8B	$36.4B	$38.0B	$34.3B	$31.0B	$28.0B	$30.9B
Long-term debt	$9.67B	$10.3B	$9.69B	$21.5B	$21.2B	$22.2B	$19.1B	$16.7B	$15.5B	$18.4B
Shareholders' equity	$23.0B	$26.4B	$28.2B	$30.3B	$39.8B	$45.2B	$50.1B	$53.5B	$49.5B	$52.5B
Cash flow
Operating cash flow	$3.52B	$3.48B	$4.02B	$3.95B	$6.21B	$8.36B	$8.52B	$7.16B	$6.69B	$6.42B
Capital expenditure	$589.6M	$570.7M	$584.0M	$636.0M	$791.0M	$1.24B	$1.12B	$1.38B	$1.39B	$1.16B
Free cash flow	$2.93B	$2.91B	$3.44B	$3.32B	$5.42B	$7.12B	$7.40B	$5.78B	$5.30B	$5.26B
Dividends paid	$399.8M	$378.3M	$433.0M	$527.0M	$615.0M	$742.0M	$818.0M	$821.0M	$768.0M	$878.0M
Share buybacks	—	—	—	—	—	—	$0	$0	$5.98B	$3.09B

RevenueNet incomeNet margin (right axis, %)

Danaher Corporation quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$5.80B	$6.54B	$5.74B	$5.94B	$6.05B	$6.84B	$5.95B	$6.26B
Growth (year over year)	+3.1%	+2.1%	−0.9%	+3.4%	+4.4%	+4.6%	+3.7%	+5.5%
Gross profit	$3.40B	$3.89B	$3.51B	$3.52B	$3.52B	$3.97B	$3.59B	$3.61B
Gross margin	58.7%	59.5%	61.2%	59.3%	58.2%	58.0%	60.3%	57.6%
Operating income	$958.0M	$1.43B	$1.27B	$760.0M	$1.15B	$1.50B	$1.34B	$1.13B
Operating margin	16.5%	21.8%	22.2%	12.8%	19.1%	22.0%	22.6%	18.0%
Net income	$818.0M	$1.09B	$954.0M	$555.0M	$908.0M	$1.20B	$1.03B	$870.0M
Net margin	14.1%	16.6%	16.6%	9.3%	15.0%	17.5%	17.3%	13.9%
EPS (diluted)	$1.12	$1.50	$1.32	$0.77	$1.27	$1.69	$1.45	$1.23
Balance sheet
Cash and equivalents	$2.63B	$2.08B	$1.99B	$2.96B	$1.53B	$4.62B	$5.70B	$4.35B
Total assets	$80.6B	$77.5B	$79.1B	$81.6B	$79.9B	$83.5B	$83.5B	$92.4B
Total liabilities	$29.3B	$28.0B	$28.3B	$29.3B	$28.8B	$30.9B	$30.6B	$39.8B
Long-term debt	$16.3B	$15.5B	$16.0B	$16.9B	$16.8B	$18.4B	$17.6B	$25.1B
Shareholders' equity	$51.3B	$49.5B	$50.8B	$52.3B	$51.1B	$52.5B	$52.9B	$52.6B
Cash flow
Operating cash flow	$1.51B	$2.02B	$1.30B	$1.34B	$1.66B	$2.12B	$1.32B	$1.53B
Capital expenditure	$298.0M	$516.0M	$245.0M	$248.0M	$292.0M	$371.0M	$237.0M	$269.0M
Free cash flow	$1.22B	$1.50B	$1.05B	$1.09B	$1.37B	$1.75B	$1.08B	$1.26B
Dividends paid	$196.0M	$195.0M	$194.0M	$229.0M	$229.0M	$226.0M	$226.0M	$283.0M
Share buybacks	$640.0M	$809.0M	$1.08B	$0	$2.01B	$0	$0	$894.0M

From Danaher Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Danaher Corporation

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.

Source: Wikipedia — Danaher Corporation